Company
Satsuma Pharmaceuticals
Our first approved product is indicated for the acute treatment of migraine with or without aura in adults.
Also known as Satsuma Pharmaceuticals, Inc.
- Status
- Operatingas of 2026-09-18
- Founded
- 2016
- Legal name
- Satsuma Pharmaceuticals, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are a pre-commercial biopharmaceutical company dedicated to bringing a novel treatment to people living with migraine. We currently have one FDA approved treatment indicated for the acute treatment of migraine.
Funding snapshot
- Total raised
- $12.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $12.1M2016-12-16
Funding rounds
- Round, 2016
- $12.1M2016-12-16, SEC form D sold, 4 investors
Products
- Other
- SMART Platform
- Other
- STS101 (Dihydroergotamine Nasal Powder)
Loading relationship preview